Home » Novartis and Speedel at Loggerheads Over Tekturna Royalties
Novartis and Speedel at Loggerheads Over Tekturna Royalties
Speedel has had a major falling-out with its fellow Swiss — but much bigger — partner Novartis over monies that the former believes it is owed relating to the new antihypertensive Tekturna/Rasilez.
Pharma Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May